Mugdha Agrawal, MD
Rheumatology · Voorhees, NJNPI 1144595414
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 369 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,354 and has fallen 78.4% since, to $724 in 2025.
Across 369 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$1K
- Johnson & Johnson$641
- Pfizer$600
- Novartis$436
- Lilly USA, LLC$375
- plus $2K from 21 others
Across 5 payments — averaging $8938.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$45K
What the payments were for
- Food & beverage$6,73696%
- Education$2464%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 90 | $1,395 |
| Amgen(2 entities) | 69 | $1,259 |
| Johnson & Johnson | 23 | $641 |
| Pfizer | 29 | $600 |
| Novartis | 21 | $436 |
| Lilly USA, LLC | 23 | $375 |
| E.r. Squibb & Sons, L.L.C. | 29 | $362 |
| Bristol Myers Squibb | 11 | $355 |
| Genentech USA, Inc. | 12 | $253 |
| AstraZeneca(2 entities) | 11 | $185 |
| UCB, Inc. | 9 | $173 |
| Mallinckrodt Hospital Products Inc. | 8 | $173 |
| Aurinia Pharma U.S., Inc. | 1 | $125 |
| Boehringer Ingelheim | 4 | $115 |
| GSK | 7 | $105 |
| Sobi, Inc | 4 | $96 |
| Mallinckrodt Enterprises LLC | 2 | $62 |
| Regeneron Healthcare Solutions, Inc. | 3 | $53 |
| Silvergate Pharmaceuticals, Inc. | 2 | $40 |
| Sanofi | 2 | $39 |
| Boston Scientific | 2 | $33 |
| Actelion Pharmaceuticals US, Inc. | 1 | $27 |
| Medexus Pharma, Inc. | 2 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Gilead | 1 | $13 |
| Radius Health, Inc. | 1 | $13 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,981 in reported general payments places this provider in the 70th percentile of 234 rheumatology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Sensoready (2 Pens)Secukinumab | 14 | $99,359 |
| Humira(Cf)Adalimumab | 12 | $80,048 |
| MethotrexateMethotrexate Sodium | 182 | $5,245 |
| Hydroxychloroquine Sulfate | 81 | $4,239 |
| Leflunomide | 54 | $2,576 |
| Colchicine | 11 | $968 |
| Sulfasalazine | 33 | $936 |
| Prednisone | 167 | $868 |
| Tramadol Hcl | 73 | $587 |
| Allopurinol | 47 | $576 |
| Gabapentin | 48 | $544 |
| Duloxetine Hcl | 25 | $474 |
| Sulfasalazine DrSulfasalazine | 16 | $462 |
| Pregabalin | 24 | $376 |
| Alendronate Sodium | 50 | $331 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira(Cf) | $1,395 | $80,04812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 234 rheumatology providers in New Jersey.
Other rheumatology in Voorhees
- Adrienne HollanderVoorhees$214K
- Joshua SundharVoorhees$137K
- James DwyerVoorhees$35K
- Lori CoxNew Brunswick$1.4M
- Richard HaddadRed Bank$1.1M
- Kiren SahniWest Long Branch$569K
- Jeffrey GreenbergSummit$399K
- Steven GolombekDover$318K
- Nicholas ScarpaJersey City$281K
- Edward AllegraRed Bank$212K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.